Navigation Links
Drug offers promising approach to improve outcome for children with high-risk leukemia
Date:11/15/2013

Combining the drug gemtuzumab ozogamicin (GO) with conventional chemotherapy may improve the outcome of bone marrow transplantation for some children battling high-risk acute myeloid leukemia (AML), according to a study led by St. Jude Children's Research Hospital. The results appear in the current edition of the journal Cancer.

For young AML patients with suitable bone marrow donors, transplantation offers the best chance of a cure. Being free of even low levels of detectable cancer cells prior to transplantation is associated with better patient survival. This analysis found that combination therapy helped to eliminate minimal residual disease (MRD) in young AML patients who initially had a poor response to chemotherapy. By reducing MRD levels prior to transplantation, it is likely that GO contributed to the excellent outcome of these patients, researchers said.

The drug, trade named Mylotarg, received accelerated approval from the U.S. Food and Drug Administration in 2000 for treatment of AML in adults. The drug was voluntarily withdrawn in 2010 following questions about its safety and efficacy. Since then several studies conducted while the drug was authorized reported promising results in adults with AML. Those reports prompted this analysis of pediatric AML patients who received GO in a clinical trial conducted while the drug was available.

Researchers said the results add to evidence that both adults and children battling AML may benefit from treatments that use a similar mechanism as GO to combat AML. The drug was not associated with severe toxicity in this or other recent studies.

Unlike traditional chemotherapy that kills rapidly dividing cells, both malignant and healthy, GO was designed to kill more selectively. The drug works by targeting a protein carried on the surface of about 90 percent of AML cells. Work has begun on new strategies, including antibody-based therapies, that target the same AML surface protein, said the study's senior author Jeffrey Rubnitz, M.D., Ph.D., a member of the St. Jude Department of Oncology.

AML is diagnosed in about 500 children annually and accounts for about 20 percent of childhood leukemia. The disease affects white blood cells.

"Currently there are few options for AML patients who relapse or do not respond to conventional therapy," said first author Carol O'Hear, M.D., Ph.D., a St. Jude postdoctoral oncology fellow. Added Rubnitz: "Without new agents, it is unlikely we will be able to improve pediatric AML survival beyond current levels of about 70 percent. The results of this and earlier studies make a strong case that some patients benefit from this targeted therapy, which has us looking for new ways to take aim at the same protein."

This study involved a subset of patients enrolled in a clinical trial of pediatric AML called AML02. Altogether, 232 children with AML enrolled in the six-year, multicenter trial that ended in 2008. A total of 46 patients received GO alone or in combination with conventional chemotherapy.

For this analysis, researchers wanted to know if GO was associated with reduced MRD. Patients were considered free of MRD if less than one cancer cell could be detected in 1,000 normal bone marrow cells.

Seventeen patients received GO alone when MRD was detected after two rounds of chemotherapy with the drugs cytarabine, daunorubicin and etoposide. After GO treatment, leukemia declined in 14 of the 17 patients and fell to undetectable levels in 13 patients.

An additional 29 patients received GO as part of their second round of three-drug chemotherapy. All had levels of residual disease that indicated a poor initial response to chemotherapy alone, including nine with MRD levels of 25 percent or more. Residual disease fell to undetectable levels in four of the nine patients following combination therapy.

Malignant cells fell to undetectable levels in 45 percent, or nine of the remaining 20 patients whose second round of treatment included GO plus chemotherapy. The patients all had MRD of between 1 and 25 percent after the first round of chemotherapy.

The overall five-year survival level of the 20 patients was 55 percent, compared to 36 percent for 22 patients with similar MRD who received chemotherapy alone. The survival difference between the two groups was not statistically significant, but investigators said the results point to a possible benefit of GO treatment for some pediatric AML patients whose cancer remained following chemotherapy. The 22 patients were treated early in AML02 before the protocol was revised to expand the use of GO. The revision followed evidence that the drug was well tolerated by the young AML patients.


'/>"/>

Contact: Summer Freeman
summer.freeman@stjude.org
901-595-3061
St. Jude Children's Research Hospital
Source:Eurekalert  

Related medicine news :

1. Absolute Bird Control Offers Complete Line of Woodpecker Deterrents
2. Spectrum Surgical Offers a Range of Surgical Instrument Education Programs and Products for Ongoing Training and to Make Patients Safer
3. Medorizon Offers EMR and ICD-10 Training to Help Medical Community with Change
4. 4leafcity.com Is Launching Special Offers On Its Cardigan Sweaters For Men
5. UC Davis Children's Hospital Offers Access to Pediatric Subspecialty Care for Rural Newborns With PEANUT Program
6. Winter Issue of ChopChop Magazine Offers Edible Gift Ideas for Kids to Make for Family and Friends
7. Asbestos Found in Winnebago County Jail, Florida Asbestos Testing Company AGC Environmental Offers Tip How to Avoid the Mineral Fiber's Fatal Health Effects
8. Goji Advance Weight Loss Formula Offers and Deals: Now Customers Can Get One Extra Bottle on Select Packages
9. Venapro: The Natural Hemorrhoids Treatment Product Now Offers 50% Discount on Select Packages for Limited Time
10. Adventure To Fitness Offers Trial Weekend For Thanksgiving
11. Best Mattress Brand Offers Tips for Winter Health and Better Sleep in Latest Article
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drug offers promising approach to improve outcome for children with high-risk leukemia
(Date:1/15/2017)... ... 2017 , ... Wondering where to go this Valentine's Day? Well, there is ... a romantic, lobster feast in the comfort of your own home. Lobster Gram is ... will be featured until February 15th, 2017. , Romantic Dinner one is Lobster ...
(Date:1/14/2017)... Saint Petersburg, Florida (PRWEB) , ... January 14, 2017 , ... ... The Emoji Scale. , The Emoji Scale is now available on Apple as ... to give emoji ratings simply by choosing one of the ten color coded values ...
(Date:1/13/2017)... ... 13, 2017 , ... KOAMTAC ®, Inc., a leading manufacturer of Bluetooth ... companion scanner and data collector at the National Retail Federation’s Big Show (NRF17) held ... answer to the market’s need for more compact and rugged devices for collecting barcode ...
(Date:1/13/2017)... (PRWEB) , ... January 13, 2017 , ... "We wanted ... attractive to wear," said one of two inventors from Virginia Beach, Va. , They ... normally mundane braces. , The accessories allow braces to be customized to suit ...
(Date:1/13/2017)... ... January 13, 2017 , ... As the nation watches ... of deans of colleges and schools of education across the country is urging a ... a Declaration of Principles released today, 175 deans sounded the alarm: “Our children suffer ...
Breaking Medicine News(10 mins):
(Date:1/13/2017)... , Jan. 13, 2017 Eli Lilly and ... (NASDAQ: INCY ) announced today that the ... review period for the new drug application (NDA) for ... of moderate to severe rheumatoid arthritis (RA). The NDA ... 2016. The FDA extended the action date ...
(Date:1/13/2017)... York , January 13, 2017 ... prevalence of AIDS will collectively contribute to the demand for ... to reach a value of US$ 551.0 Mn by 2016 ... will remain the most lucrative markets for western blotting, whereas ... the market globally. ...
(Date:1/13/2017)... cattle, leafy greens and rosy cheeked children share space in ... the food industry,s shift from response to prevention. ... Swab Rinse Kit (SRK™) is an efficient, ... wake of the new FDA Food Safety Modernization Act ... expanding the U.S. production of the SRK line at our ...
Breaking Medicine Technology: